|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2006
Decision Resources, Inc., March 2007, Pages: 22
Introduction:
Implementation and refinement of existing pricing and reimbursement initiatives throughout the major pharmaceutical markets continued to be a major theme in the fourth quarter of 2006. In the United States, preparations continued for the second year of the Medicare Part D prescription drug benefit. In Europe, while the European Union took action to promote common standards for health technology assessment, individual governments continued to pursue independent national cost-containment strategies. And in Japan, implementation of revised price premiums earlier in the year has benefited manufacturers of useful and innovative drugs.
Get the Answers You Need to Shape Your Strategy:
In the United States, the midterm Congressional elections dominated the news. What implications will this change of power have on U.S. health care policy? How will the pharmaceutical and biotechnology industries respond to this new political landscape?
The German government has proposed significant health care reforms. How will these reforms affect health insurance, physician reimbursement, hospitals, and the pharmaceutical market? What new freedoms and what new constraints will result?
Governments in the major pharmaceutical markets continue to refine regulations on drug pricing and reimbursement. How will these refinements affect the pharmaceutical markets in these countries? Will certain drug classes in certain countries actually benefit from these reforms?
The steady expansion of reference pricing across Europe exemplifies governments’ tendency to imitate each other, while they simultaneously pursue their disparate national strategies for containing health care costs. In such a climate, is there any hope for harmonized reimbursement standards?
Scope:
Fourth quarter news in 2006: major events in the pharmaceutical pricing, reimbursement, and prescribing environment in the United States, Europe (France, Germany, Italy, Spain, and the United Kingdom), and Japan.
Cost-containment programs: measures that health care payers are using to curb their drug expenditures and to improve patient access to medications.
Outlook: our assessment of the implications of these events for the pharmaceutical industry in the major markets under study.
Also available
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2006
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Second Quarter of 2006
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2006
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2007
Pharmaceutical Pricing and Reimbursement in the United States, 2008
Customers who bought this item also bought
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2007
Pharmaceutical Pricing and Reimbursement in the United States, 2008
Pharmaceutical Pricing and Reimbursement in the United Kingdom, 2008
Strategic Overview of Pharmaceutical Pricing and Reimbursement in the Major Markets
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2007
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Second Quarter of 2007
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2008
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2008
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2007
Pharmaceutical Pricing and Reimbursement in Japan, 2008
Special Report: Pharmaceutical Pricing and Reimbursement in Germany, 2008
Pricing and Reimbursement in the United Arab Emirates
|
|
|
|
